Genomic Vision SA
PAR:GV
Genomic Vision SA
PAR:GV
Price:
0.0018
EUR
Market Cap:
€694.6k
Relative Value
There is not enough data to reliably calculate the relative value of GV.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
GV
Relative Value
Base Case
Not Available
Multiples Across Competitors
GV Competitors Multiples
Genomic Vision SA Competitors
Genomic Vision SA Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| FR |
|
Genomic Vision SA
PAR:GV
|
693.2k EUR | 0.6 | -0.1 | -0.2 | -0.2 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
388.5B USD | 6.4 | 92.8 | 15.3 | 21.2 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
194.6B USD | 5.3 | 25.2 | 14.6 | 14.6 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
179.2B USD | 6.1 | 21.1 | 13.1 | 16.2 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
117.5B USD | 9.8 | 29.7 | 22.4 | 23.4 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80.2B USD | 5.6 | 17.8 | 13.3 | 15.1 | |
| AU |
|
CSL Ltd
ASX:CSL
|
67.1B AUD | 3.1 | 34.1 | 11.3 | 14.2 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
37.8B EUR | 10.7 | 34.2 | 37.1 | 37.8 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
